Ann: Quarterly Report and Appendix 4C, page-59

Antisense is also active in filing new patent applications to protect the use of ATL1102.Just recently, the company said that its international patent application titled “Methods for treating multiple sclerosis using antisense oligonucleotides” advanced to the national phase in the US, Australia, New Zealand, Canada and Europe.If granted, this patent family will protect the use of ATL1102 in MS until 2038, with a further five-year extension available in the US, Australia and Europe.————

Anp is the only Biotech Worldwide to use CD49d in its treatment for inflammation and diseases associated with it…You will find that the patent will cover all new diseases until 2038 and beyond….Thus making Atl1102 very attractive to Big Pharma.Get Outlook for iOS